Evidence mapPaperPMID 41145344Full record

SynthesisThe journal of prevention of Alzheimer's disease2025

Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches.

Erika Bereczki, Francesca Mangialasche, Mariagnese Barbera, Paola Padilla, Yuko Hara, Howard Fillit, Alina Solomon, Miia Kivipelto

Abstract readSystematic Review
In one paragraph

Synthesis in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. System changes to empower primary care in Alzheimer's disease detection and care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Erika BereczkiFINGERS Brain Health Institute, Karolinska Vägen 37A, QA32 171 64, Solna, Sweden; Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Visionsgatan 4 171 64, Solna, Sweden. Electronic address: Erika.bereczki@fbhi.se.
Francesca MangialascheFINGERS Brain Health Institute, Karolinska Vägen 37A, QA32 171 64, Solna, Sweden; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A 171 64, Solna, Sweden; Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Karolinska Vägen 37A 171 76, Solna, Sweden. Electronic address: Francesca.mangialasche@ki.se.
Mariagnese BarberaDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C 70211, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK.
Paola PadillaFINGERS Brain Health Institute, Karolinska Vägen 37A, QA32 171 64, Solna, Sweden; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A 171 64, Solna, Sweden.
Yuko HaraAlzheimer's Drug Discovery Foundation, 57 West 57th St. Suite 904, New York, NY 10019, USA.
Howard FillitAlzheimer's Drug Discovery Foundation, 57 West 57th St. Suite 904, New York, NY 10019, USA.
Alina SolomonDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A 171 64, Solna, Sweden; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C 70211, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK.
Miia KivipeltoFINGERS Brain Health Institute, Karolinska Vägen 37A, QA32 171 64, Solna, Sweden; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A 171 64, Solna, Sweden; Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Karolinska Vägen 37A 171 76, Solna, Sweden; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK; Research and Development Unit, Stockholms Sjukhem, Stockholm, Sweden; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To effectively combat dementia onset and progression, lifestyle-based interventions targeting multiple risk factors and disease mechanisms through a multidomain approach - tailored and implemented early in the disease process - have emerged as promising. Electronic databases and relevant websites (clinicaltrials.gov, euclinicaltrials.eu, PubMed and EMBASE) were systematically searched for randomized controlled trials (RCTs) testing the combination of multidomain lifestyle and pharmacological interventions. Studies were included if 1) lifestyle intervention was multimodal (≥2 domains); 2) it was combined with drugs, supplements, or medical food; 3) the study population was within the Alzheimer's disease (AD) and related dementias continuum, including cognitively normal individuals at-risk for dementia, people with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or prodromal AD; 4) outcomes included cognitive or dementia-related measure(s), and 5) intervention lasted at least 6 months. Twelve combination RCTs were identified, incorporating 2 to 7 lifestyle domains (physical exercise, cognitive training, dietary guidance, social activities, sleep hygiene, cardiovascular/metabolic risk management, psychoeducation or stress management), combined with pharmacological components (e.g., Omega-3, Tramiprosate, vitamin D, BBH-1001, epigallocatechin gallate, Souvenaid, and metformin). Seven RCTs targeted participants with prodromal AD, MCI or early dementia, five focused on at risk individuals or SCD. Additionally, 2 studies adopted a precision medicine approach by enriching populations with APOE-ε4 carriers. Findings suggest that well-designed interventions - tailored to the right individuals, implemented at the optimal time - may effectively improve cognition. However, further refinement of the RCT methodology is warranted, for better alignment with the multifaceted nature of dementia prevention and management.

Indexed as

Alzheimer DiseaseDietary SupplementsLife StylePrecision MedicineRisk Reduction BehaviorCognitive DysfunctionHumansRandomized Controlled Trials as TopicCombination therapyDementia preventionMultidomain lifestyle interventionPharmacological approachRandomized controlled trial

Identifiers

PMID41145344
PMCPMC12627892

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.